Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (NASDAQ: PSNL) announced its relocation of corporate headquarters and Clinical Laboratory from Menlo Park to a new 100,000 sq. ft. facility in Fremont, aimed at supporting growth and expanding laboratory operations. The 13-year lease on the new facility, nearly doubling their existing space, reflects the company's ambition to enhance its presence in the cancer diagnostics market. CEO John West emphasized the intention to recruit top talent to meet business goals and strengthen R&D efforts. The move is expected to occur within the next 12 months.
Personalis, Inc. (Nasdaq: PSNL) reported record revenue of $21.7 million for Q2 2021, an 11% increase from $19.5 million in Q2 2020. The revenue from biopharma and other customers, excluding the VA MVP, grew 72% to $8.2 million. The company ended the quarter with cash and investments totaling $328.9 million. Despite achieving growth, Personalis faced a net loss of $15 million and an anticipated net loss of $65 million to $70 million for 2021. Looking ahead, Q3 revenue is expected to be around $22.2 million.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced its participation in the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 17, 2021. The company specializes in population sequencing and cancer genomics, focusing on providing comprehensive molecular data from a single tissue sample through the Personalis® ImmunoID NeXT Platform®. Additionally, Personalis is the sole sequencing provider to the VA MVP, emphasizing its commitment to quality and efficiency in oncology.
Personalis, Inc. (Nasdaq: PSNL) announced a study published in Clinical Cancer Research detailing the Personalis Neoantigen Presentation Score (NEOPS™), a new biomarker for predicting immunotherapy response in advanced melanoma patients. NEOPS, developed through extensive tumor profiling, outperformed traditional biomarkers like tumor mutational burden. The study involved late-stage melanoma patients and highlighted NEOPS's potential to enhance precision oncology. Personalis aims to utilize NEOPS for broader clinical applications, contributing to advancements in cancer screening and treatment.
Personalis, Inc. (Nasdaq: PSNL) will announce its Q2 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for the same day at 2:00 PM PT / 5:00 PM ET to discuss the results and recent developments. Interested parties can join the live call via phone or access the webcast through the company's investor relations website. Personalis is recognized for its advancements in cancer genomics and population sequencing, operating a significant global sequencing operation while serving the VA MVP.
Personalis, Inc. (Nasdaq: PSNL) announced the NeXT Level Biomarkers Symposium, showcasing innovative research in cancer genomics, particularly through their NeXT Platform. The event will feature presentations on HLA loss of heterozygosity, neoantigen prediction, and the Neoantigen Presentation Score (NEOPS). Additionally, a case study from the Parker Institute for Cancer Immunotherapy will be highlighted. Richard Chen, CSO, expressed excitement about sharing advancements aimed at precision oncology. Further details and registration are available on their official website.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will participate in the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. This event will showcase the company’s advancements in population sequencing and the ImmunoID NeXT Platform, which offers comprehensive molecular data on cancer and immune response. The presentation will be available for 90 days on Personalis’ website, emphasizing their role as the sole sequencing provider for the U.S. Department of Veterans Affairs Million Veterans Program.
Personalis, Inc. (Nasdaq: PSNL) will present at Biomarkers Week Online 2021, showcasing the ImmunoID NeXT Platform for cancer immunogenomics. Erin Newburn, MS, PhD, will detail its capability to analyze tumor and immune microenvironment from a single sample. A case study on 51 late-stage melanoma patients highlights the platform's effectiveness in predicting responses to checkpoint blockade. Personalis is a co-sponsor of the event and aims to discuss its innovations in cancer genomics.
Personalis, Inc. (Nasdaq: PSNL) reported a record revenue of $20.9 million for Q1 2021, marking a 9% increase from $19.2 million in Q1 2020. Revenue from biopharma and other customers surged 74% to $7.7 million. The company added $162 million from a public offering, ending the quarter with $353.4 million in cash and equivalents. Despite these gains, net loss rose to $12.4 million, consistent with a net loss per share of $0.29. Outlook for Q2 2021 anticipates revenues of approximately $21.3 million and a net loss of $16 million to $17 million.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
